Evidence map›Paper›PMID 39649217›Full record

ArticleWorld journal of gastrointestinal surgery2024

Pembrolizumab in patients with gastric cancer and liver metastases: A paradigm shift in immunotherapy.

Grigorios Christodoulidis, Dimitra Bartzi, Konstantinos Eleftherios Koumarelas, Marina Nektaria Kouliou

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastrointestinal surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Grigorios ChristodoulidisDepartment of General Surgery, The University Hospital of Larissa, The University of Thessaly, Larissa 41110, Greece. gregsurg09@gmail.com.
Dimitra BartziDepartment of Oncology, The 251 Airforce General Hospital, Athens 11525, Greece.
Konstantinos Eleftherios KoumarelasDepartment of Emergency Medicine, The General Hospital of Larissa, Larissa 41221, Greece.
Marina Nektaria KouliouDepartment of General Surgery, The University Hospital of Larissa, Larissa 41110, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this editorial, we explore the impact of immunotherapy and its safety in patients with advanced gastric cancer (GC) and liver involvement. GC, a formidable adversary in the oncology landscape, presents its most challenging battlefront when it reaches stage IV, often characterized by liver metastases. The prognosis for patients at this advanced stage is daunting, with systemic chemotherapy traditionally offering a median overall survival slightly over a year. However, the landscape of treatment is evolving, with new strategies and therapies offering a glimmer of hope.

Indexed as

Gastric cancerImmunotherapyLiver metastasisPembrolizumabPrognosisTreatment

Identifiers

PMID39649217
PMCPMC11622097

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.